Mucinous carcinoma
Education on Mucinous carcinoma and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Mucinous carcinoma and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Mucinous carcinoma?
Mucinous carcinoma is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. It is also known as breast cancer. Cancer involves abnormal cell growth. The patent discusses how neutrophil elastase and low circulating AAT may influence tumor development and spread.
What Mark Egly's patent discusses
Many forms of breast cancer exist, including: metastatic breast cancer ("MBC"), ductal carcinoma in Situ ("DCIS"), invasive ductal carcinoma ("IDC"), triple negative breast cancer, inflammatory breast cancer ("IBC"), medullary, tubular carcinoma, mucinous carcinoma, Paget disease, small cell carcinoma of the breast, and non- small cell cancer.
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Mucinous carcinoma, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Mucinous carcinoma, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: